top of page
Recent Posts

FDA Approves Vidaza for Rare Pediatric Blood Cancer

  • OPACC
  • May 24, 2022
  • 1 min read

The Food and Drug Administration (FDA) approved Vidaza (azacytidine) for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia, a rare blood cancer where certain types of white blood cells do not mature normally.


Comments


Archive
Search By Tags
Rama logo.png
cgcg logo.jpg

524 Bayfield Street North
P.O. Box 20005
Barrie, ON L4M 5E9
Canada

info@opacc.org

705-828-7965

  • Wix Facebook page
  • Wix Twitter page
  • Instagram Social Icon
  • YouTube Social  Icon
bottom of page